THE SCIENCE AND TECHNOLOGY FOR EXTENDING HEALTHY HUMAN LIFESPAN I Future Investment Initiative 6th Edition
NOW: Global life expectancy has doubled from 30 years to 73 years over the last two centuries. Technologies like the genomic-editing tool, CRISPR, as well as discoveries in vaccine therapy and advanced drug development, have led to the prediction that most children born this millennium will live to one-hundred years old. However, today, people spend more absolute years in poor health than before, while global inequality among the elderly widens. Longevity researchers now claim that the focus should shift to quality – not just quantity – in the later stages of life.
NEXT: What new biotech developments will define this new era in longevity research? Is it wise to invest in therapies that turn once deadly diseases into chronic yet manageable conditions? How should investors prioritize when deciding which longevity technologies to support?
SPEAKERS
● Dr. Nichola Conlon, PhD, Co-Founder & CEO, Nuchido Laboratories
● Dr. Peter H. Diamandis, MD, Executive Chairman, XPRIZE & Fountain
Life; Board Member, Future Investment Initiative Institute
● Robert Hariri, MD, PhD, Chairperson, Founder, & CEO, Celularity
● Dr. Mehmood Khan, CEO, Hevolution Foundation
MODERATOR
● Dr. Aubrey De Grey, Scientific Founder, SENS Research Foundation
34